Sepsis remains a major global health threat, with its disease burden clearly decreasing in children and increasing in adults
It is just mind boggling how the largest payer of biopharmaceuticals in this country, the federal government, has no audit rights, and oftentimes relies on faulty data, which are dated, or is based on estimates, or based on worse, testimonies of PBM or insurer, pharmacy manager or insurer executives, and they rely on those type of data points to make these massive policy decisions
If true, does Lilly have an obligation to update its studies, and its comparative advertising, when Novo improves its product
Many people do report significantly less hunger which can be helpful, but also increases the risk of inadequate nutrient intake if meals become too small or too infrequent
Inside the GLP-1 Boom: What a Biotech Analyst and PhD/Nutritionist Thinks Mini-deep dive on the fastest growing healthcare opportunity from an investment and health perspective This is for: Science enthusiasts Pharma/biotech consultants, analysts Investors in the life science space Doctors, nutritionists, health coaches, fitness coaches People considering or already on weight loss medication Longevity enthusiasts I help you: Understand what weight loss medications are Get a list of the key obesity players in the pharma/biotech space Understand lifestyle strategies to get the best outcomes out of GLP1s Free Resources included: Obesity development landscape and launch timelines Weight loss data from key drugs in development Comment Health and I will share a US market model template to help you forecast weight loss drug sales yourself See inside for disclosure Intro to Weight Loss Medications (WLMs) Unless you are living under a rock, the words GLP1, Ozempic, Wegovy, Mounjaro, weight-loss medication must not be new to you
